UK Markets close in 4 hrs 28 mins

GlaxoSmithKline plc (GSK.L)

LSE - LSE Delayed price. Currency in GBp
Add to watchlist
1,420.09+9.29 (+0.66%)
As of 11:47AM BST. Market open.
Full screen
Previous close1,410.80
Bid1,419.80 x 0
Ask1,420.20 x 0
Day's range1,409.20 - 1,420.80
52-week range1,190.80 - 1,528.80
Avg. volume6,682,818
Market cap71.452B
Beta (5Y monthly)0.40
PE ratio (TTM)13.63
EPS (TTM)104.20
Earnings date27 Oct 2021
Forward dividend & yield0.80 (5.57%)
Ex-dividend date20 May 2021
1y target estN/A
  • Motley Fool

    Why 23andMe Stock Has Jumped 16% So Far This Week

    What happened Shares of the genetic-testing company 23andMe (NASDAQ: ME) gained another 16% through Thursday's close this week, according to data from S&P Global Market Intelligence. The biotech's stock is now up by more than 34% over the past two weeks.

  • Yahoo Finance Video

    Doctor on Covid-19: ‘This is a virus that is really here to stay’

    Dr. Elizabeth Clayborne, Adjunct Assistant Professor of Emergency Medicine at the University of Maryland School of Medicine and Emergency Physician at UM Capital Region Medical Center, joins Yahoo Finance to discuss the latest in the coronavirus pandemic.

  • Motley Fool

    Johnson & Johnson May Not Have to Wait Long for Its Next Blockbuster Vaccine

    While Pfizer and BioNTech's Comirnaty and Moderna's COVID-19 vaccine have dominated the discussion surrounding COVID-19 vaccines, Johnson & Johnson's (NYSE: JNJ) COVID-19 vaccine has also positioned itself for blockbuster status. For instance, Johnson & Johnson's COVID-19 vaccine is expected to bring in $2.5 billion for the pharma stock this year alone. Let's discuss the clinical results of Johnson & Johnson's RSV vaccine candidate to date, as well as its sales potential to understand why this could be Johnson & Johnson's next blockbuster vaccine.